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Abstract
Background: Spindle cell tumors of the larynx are rare. In some cases, the dignity is difficult to
determine. We report two cases of laryngeal spindle cell tumors.
Case presentation: Case 1 is a spindle cell carcinoma (SPC) in a 55 year-old male patient and
case 2 an inflammatory myofibroblastic tumor (IMT) in a 34 year-old female patient. A
comprehensive morphological and immunohistochemical analysis was done. Both tumors arose at
the vocal folds. Magnified laryngoscopy showed polypoid tumors. After resection, conventional
histological investigation revealed spindle cell lesions with similar morphology. We found
ulceration, mild atypia, and myxoid stroma. Before immunohistochemistry, the dignity was
uncertain. Immunohistochemical investigations led to diagnosis of two distinct tumors with
different biological behaviour. Both expressed vimentin. Furthermore, the SPC was positive for
pan-cytokeratin AE1/3, CK5/6, and smooth-muscle actin, whereas the IMT reacted with antibodies
against ALK-1, and EMA. The proliferation (Ki67) was up to 80% in SPC and 10% in IMT. Other
stainings with antibodies against p53, p21, Cyclin D1, or Rb did not result in additional information.
After resection, the patient with SPC is free of disease for seven months. The IMT recurred three
months after first surgery, but no relapses were found eight months after resurgery.
Conclusion: Differential diagnosis can be difficult without immunohistochemistry. Therefore, a
comprehensive morphological and immunohistochemical analysis is necessary, but markers of cell
cycle (apart from the assessment of proliferation) do not help.
Background
The most common type of malignant laryngeal tumors is
the classical squamous cell carcinoma (SCC). Benign
tumors of the larnyx are divided in two groups: mesenchy-
mal and epithelial lesions. The latter harbours particular
papillomas, whereas simple vocal cord polyps, Reinke
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edema, or e.g. leiomyomas have a mesenchymal origin. A
further group are tumorous inflammatory lesions, such as
granulomatous polyps. Most of these different entities
show a characteristic histomorphology, so that the diag-
nosis might be unproblematic for the histopathologist.
Spindle cell lesions of the larynx are rare (1.3%) [1]. Such
tumors usually require immunohistochemical investiga-
tions for detailed histopathological specification. In some
cases, the dignity is difficult to determine.
We demonstrate a spindle cell carcinoma (SPC) and an
inflammatory myofibroblastic tumor (IMT), two laryn-
geal spindle cell tumors with complete different dignity,
and discuss the differential diagnosis focusing on the
immunohistochemical results.
Case presentation
Clinical data
Case one
A 55 year-old male patient with relapsing dyspnoe and
five pneumonias within the last four years was referred to
our ENT hospital with progressive dyspnoe and dyspho-
nia for five months. The patient was a smoker with 30
pack years, no alcohol abuse. He did not show any other
systemic symptoms. Flexible transnasal laryngoscopy
showed a laryngeal mass without visible glottis. Subse-
quently, microlaryngoscopy with laser resection of the
ulcerated tumor (diameter 3 cm) was performed. The
tumor originated from the right vocal fold. Histologically,
a spindle cell carcinoma (SPC) was diagnosed. In a second
surgery no remnants were found. The cervical lymph
nodes were unsuspicious in ultrasound and computerto-
mographic investigation. Therefore, neck dissection was
not carried out. The patient is free of disease seven months
after surgery.
Case two
A 34 year-old female patient with increasing dysphonia
for one month was referred to our ENT hospital. She had
neither a history of smoking nor alcohol abuse. Magnified
laryngoscopy showed a polyp (0.8 cm) of the right vocal
fold. Examination was followed by microlaryngoscopy
with macroscopically complete resection. In a postopera-
tive control ten days after surgery, a small nodule was
found and suspected as a granulomatous polyp. Logo-
pedic therapy led to a subjective voice improvement
within the next three months. However, further magnified
laryngoscopy showed an increasing size of the nodule.
The following resection of a round tumor with 1.2 cm
diameter was macroscopically and histologically com-
plete. Eight months after surgery the patient is free of dis-
ease.
Histopathological and immunohistochemical methods
After surgical resection, routinely processed paraffin
blocks were cut at 2 μm and put on 3-aminopropyltri-
ethoxysilane (APES) coated slides. Sections were first
stained with hematoxylin-eosin (HE) and periodic acid
Schiff (PAS) reaction.
Cuts for immunohistochemistry were air-dried over night,
dewaxed, rehydrated in descending concentrations of eth-
anol before being heated for antigen unmasking in 10
mM citric acid (pH 5.5) for five minutes. After rinsing
with distilled water, slides were washed in phosphate
buffered saline (PBS). For staining, the Histostain-Plus
bulk kit (Zymed) was used according to the manufac-
turer's protocol: 15 min blocking reagent, primary anti-
body incubation for one hour, rinsing with PBS (pH 7.4),
biotinylated secondary antibody incubation for 20 min-
utes, rinsing with PBS, streptavidin peroxidase 20 min-
utes, and rinsing with PBS. Staining was performed by
adding 3,3'-diaminobenzidine (DAB, Sigma) with subse-
quent counterstaining using haemalaun. The antibodies,
sources, and dilutions used are indicated in table 1. In a
first series, standard stainings for presumed diagnoses
were carried out, a second was added obtaining further
information. After the final diagnosis, an EBER (EBV-
encoded RNA) in situ hybridization of case two was per-
formed (EBER probe Y-5200, PNA-ISH-Detection Kit K-
5201, Dako).
All stainings are used in routine investigations and the
antibodies were tested in suitable positive controls.
Results
Case one
In HE staining, an ulcerated spindle cell tumor with
widely myxoid stroma changes was found. Tumor cells
were arranged in an irregular pattern with different cell
density (figure 1a). No PAS positivity was found, necrosis
was absent. Spindle cells showed mild to moderate atypia
with prominent nucleoli. Ten high power fields (HPF)
contained a maximum of one mitosis (figure 1b), and no
atypical mitoses were found. Focally, the tumor was scant-
ily infiltrated by neutrophil granulocytes. The surface epi-
thelium was only detectable on a small focus, herein no
atypia was found in the surface epithelium. The results of
immunohistochemical investigations are indicated in
table 1. The tumor was strongly positive for vimentin (fig-
ure 1c) and different cytokeratins including the squamous
differentiation marker CK5/6 (figure 1d). Only pan-cytok-
eratin MNF116 was negative in the tumor cells, but
reacted with the surface epithelium. Smooth-muscle
(sm)-actin (figure 1e) was coexpressed. The proliferation
(determined by Ki67 staining) was up to 80 % (figure 1f).
Due to these features a spindle cell carcinoma was diag-Diagnostic Pathology 2007, 2:1 http://www.diagnosticpathology.org/content/2/1/1
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nosed. Together with the clinical information, the tumor
stage was pT2, cN0, cM0, and (after resurgery) R0.
Case two
This lesion showed an organized growth pattern of spin-
dle cells. Most of the tumor stroma was myxoid (figure
2a). The tumor had regular small blood vessels and capil-
laries similar to granulation tissue. A scanty infiltration
with inflammatory cells (dominated by lymphocytes) was
found. Plasma cells were rare, neutrophils were absent.
No necrosis was found. Tumor cells showed only mild
atypia (figure 2b). The spindle shaped nuclei presented
mostly blunt ends. Chromatin was evenly distributed,
nucleoli were not visible. We did not identify mitoses. As
proof of our final diagnosis of an inflammatory myofibrob-
lastic tumor, immunohistochemistry revealed an expres-
sion of ALK-1 (figure 2c). Corresponding to the benign
character, the proliferation (Ki67) was less than 10 % (fig-
ure 2d). Table 1 shows other results of immunohisto-
chemical investigations. The EBER in situ hybridization
did not reveal an infection with Ebstein-Bar-Virus (EBV).
The relapse was a sharply confined nodule below an intact
surface epithelium (figure 2e). The cell density was higher
and myxoid changes were absent (figure 2f). No mitoses
were found, but mild atypia. The number of inflamma-
tory cells was reduced. Immunohistochemical pattern was
identical to the primary lesion.
Apart from the diagnostic areas shown, both cases con-
tained distended spindle cell components with a high
degree of overlapping histomorphology in conventional
HE stain.
Table 1: Immunohistochemistry
Antibody Expression in SPC Expression in IMT Source/Dilution
First stainings
Vimentin * ++ ++ DAKO, mouse, 1:800
PanCytokeratin AE1/3 * +N R DAKO, mouse, 1:100
EMA + + (weak only) LOXO, mouse, 1:20
ALK-1 * NR + DAKO, mouse, 1:20
smooth muscle Actin ++ NR Beckman Coulter, mouse, 1:20
Desmin NR NR DAKO, mouse, 1:400
S100 NR NR DAKO, rabbit, 1:2000
CD34 NR NR DAKO, mouse, 1:100
CD117 NR NR DAKO, mouse, 1:100
Ki67 * ++ 60–80% + 5–10% DAKO, mouse, 1:200
Additional stainings
PanCytokeratin KL1 * +N R Beckman Coulter, mouse, 1:40
PanCytokeratin MNF116 NR (but epithelium +) NR DAKO, mouse, 1:50
Cytokeratin 5/6 + (weak only) NR DAKO, mouse, 1:50
Cytokeratin 7 NR NR DAKO, mouse, 1:20
CD68 NR NR Kiel, ascites, 1:20000
CD30 NR NR DAKO, mouse, 1:5
CD56 NR NR DAKO, mouse, 1:10
Her2Neu NR NR DAKO, rabbit, 1:100
Estrogen receptor NR NR DAKO, mouse, 1:10
Progesteron receptor NR NR DAKO, mouse, 1:10
p53 ++ DAKO, mouse, 1:20
p63 * ++ NR Neomarkers, mouse, 1:200
p21 ++ ++ Dianova, rat, 1:20
Cyclin D1 ++ LOXO, mouse, 1:20
Bcl-2 + (weak cytoplasmatic) ++ DAKO, mouse, 1:400
Rb ++ + Neomarkers, mouse 1:50
HHV 8 NR NR Tebu, rat, 1:200
HPV NR NR Virofem, mouse conc.
Used antibodies with expression pattern in spindle cell carcinoma (SPC) and inflammatory myofibroblastic tumor (IMT) as well as source and 
dilution. Staining started with antibodies in the upper part, followed by additional stainings, listed below. strong positive reaction (++), positive 
reaction (+), no reaction (NR), recommended for differential diagnosis (*).Diagnostic Pathology 2007, 2:1 http://www.diagnosticpathology.org/content/2/1/1
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Conclusion
We demonstrated two cases of laryngeal spindle cell
tumors with complete different dignity. The first case was
a spindle cell carcinoma (SPC), the second an inflamma-
tory myofibroblastic tumor (IMT). Because of similar
morphology, only comprehensive immunohistochemical
investigations allowed the correct final diagnoses and the
aligned assessment of biological behaviour.
According to the recent WHO definition, laryngeal SPCs
represent biphasic tumors, composed of a squamous cell
carcinoma (SCC), either in situ or invasive, and a malig-
nant spindle cell component with mesenchymal appear-
ance [2], but of an evident monoclonal epithelial origin
[3]. Obsolete synonyms are sarcomatoid carcinoma, carci-
nosarcoma, collision tumor, or pseudosarcoma. Males in
the 6th and 7th decade are predisposed (reported male to
female ratio is 10:1) [4,5]. The vocal fold is the most com-
mon site of involvement [5]. Risk factors correspond to
common SCC: cigarette smoking and alcohol abuse [4].
Some SPCs seem to develop after radiation [5,6], but a
strong evidence of this hypothesis is missing. The progno-
sis of SPCs is discussed controversially. One quarter
metastasizes in regional lymph nodes, distant metastases
occur in 5–15% [5]. These often contain usual SCC with
or without spindle cell component. Rarely, only the spin-
dle cell component occurs [6]. Five year survival is
reported to be 65–95% [1,5]. Low tumor stage and
absence of previous irradiation indicate a better progno-
sis. Besides, improved survival rates are associated with a
low level of cytokeratin expression [6].
The differential diagnosis includes, apart from rare laryn-
geal sarcomas, reactive or benign spindle cell prolifera-
tions, such as nodular fasciitis, IMT, or low grade
myofibroblastic sarcoma.
IMTs are neoplasms with borderline dignity [2]. They are
composed of myofibroblastic cells and intermingled
Inflammatory myofibroblastic tumor Figure 2
Inflammatory myofibroblastic tumor. 2a: Spindle cell 
lesion with more regular pattern than in 1a, myxoid degener-
ation, vessels similar to granulation tissue, infiltration with 
inflammatory cells (HE ×200). 2b: Lack of atypia in tumor 
cells, resembling regular myofibroblasts (HE ×400). 2c: Diag-
nostic expression of ALK-1 immunoperoxidase (×400). 2d: 
Low proliferation (Ki67), less 10% (immunoperoxidase 
×400). 2e: Relapse tumor, sharply confined surfaced with 
intact epithelium (HE ×40). 2f: Higher cellularity, no myxoid 
changes, less inflammatory cells, but mild atypia in the relapse 
(HE ×400).
Spindle cell carcinoma Figure 1
Spindle cell carcinoma. 1a: Spindle cell lesion with myxoid 
stroma (HE ×200). 1b: Mild to moderate atypia in tumor cells 
with rare mitoses (HE ×400). 1c: Vimentin immunoperoxi-
dase – strong expression in tumor cells (×400). 1d: Pan-
cytokeratin AE1/3 immunoperoxidase (×400). 1e: smooth 
muscle actin immunoperoxidase (×400). 1f: Proliferation 
(Ki67) up to 80% (immunoperoxidase ×200).Diagnostic Pathology 2007, 2:1 http://www.diagnosticpathology.org/content/2/1/1
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inflammatory cells, especially plasma cells [7]. Nowadays,
obsolete synonyms are inflammatory pseudotumor,
plasma cell granuloma, plasma cell pseudotumor, or
pseudosarcomatous lesion/tumor [2]. The latter is similar
to the synonymous "pseudosarcoma" for SPC and might
lead to severe misunderstandings. The most common
location is the lung, followed by soft tissue and viscera.
IMT of the head and neck, especially of the larynx, are rare
[7,8]. Coffin described 12 cases of head and neck IMTs
among 84 extrapulmonary IMTs, and only three were
located in the larynx [7]. 19 cases of laryngeal IMTs have
been reported in the literature. All cases are listed in table
2. In distinction to IMTs occuring in other sites, predomi-
nantly in children or young adults, IMTs of the larynx
affect adults with a median age of 57 years (2–74). The
male to female ratio is 1.8:1. Only one case is reported in
a child [9]. The prognosis is excellent. Metastases are pos-
sible, but were not decribed for IMTs of head and neck
and did not occur in the reported cases [7]. The recurrence
rate was 21%. Most relapses occurred within 12 months
after initial surgery, perhaps due to incomplete resection
in most instances. One problem for surgeons is the lack of
a line of demarcation surrounding the lesion. Radical sur-
gery is reserved for more aggressive cases [8-10]. However,
a total laryngectomy was necessary only in one of all IMTs
reported [8]. Some patients profit from corticosteroid [11]
and nonsteroidal anti-inflammatory treatment[12].
The etiology of IMTs is unknown. The idea of a reactive
lesion was refuted by genetic studies. The clonal origin is
evident [13,14] and chromosomal abnormalities involv-
ing 2p23 [15,16], and fusion of the ALK gene with tropo-
myosin 3 (TPM3-ALK) or tropomyosin 4 (TPM4-ALK) is
found in a subset [17]. Gene rearrangement and gene acti-
vation are restricted to the myofibroblastic component.
Some authors assume an association with a trauma.
Alaani et al. have documented a causal relation between
local laryngeal trauma and IMT [10], Wenig et al. found
an IMT after traumatic intubation [8]. Furthermore,
immunosuppression, unspecific infections, infections of
HHV8 [18] and EBV [19] were identified in IMT and an
overexpression of IL-6 and cyclin D1 (confirmed by our
investigations) have been reported [18]. In the case we
have presented, we could not affirm any infectious gene-
sis.
Clinically, IMT can mimic a neoplastic process. Patients
suffer from hoarseness, dysphonia, or foreign body sensa-
tions in the troath. Constitutional or systemic signs (fever,
weight loss, anaemia) are usually missing in extrapulmo-
nary IMTs. Systemic alterations are only reported in one
laryngeal IMT [20].
The diagnosis of IMTs can be difficult due to the wide
morphological spectrum. Coffin et al. have described
three morphologic patterns:
1. spindle cells in a myxoid background with a vascular
and inflammatory component (nodular fasciitis like)
Table 2: Synopsis of all 19 laryngeal inflammatory myofibroblastic tumors published in the English literature.
Patient, Age Symptoms Site CS Course Immunostaining
M, 62 [20] Hoarseness, dysphonia, systemic 
manifestations (fever and weight 
loss) for 3 months
True vocal cord yes FD 24 months vim +, actin +, NR: 
desmin, CK, S100, Alk-1
M, 2 [9] Snoring, apneic events Aryepiglottic fold no R 7 months *
F, 52 [11] Voice change for 12 months False cord no FD 4 years vim +, sm-actin +, NR: 
S100, desmin
F, 49 [10] Dyspnoea, stridor for 4 month, 
15 month after road accident
Subglottis no Persistence for 1 months 
after surgery, resurgery 
with persistence for 12 
months, 2nd resurgery, FD 
15 months after resurgery
sm-actin patchy +, NR: 
desmin, CK, EMA
M, 51 [32] Hoarseness for 6 months Vocal cord * FD 12 months vim+, sm-actin+, NR: CK, 
desmin, S100, CD34
M, 74 [33] Hoarseness, foreign body 
sensation, dyspnoe for several 
months
True vocal cord * FD 2 months, death on 
cardiac failure
vim +, actin +, NR: S100, 
desmin, CK
M, 57 [34] Hoarseness, dyspnoe, disphonia 
for 5 months
Anterior commissur * R 2 months, after 
resurgery FD 12 months
vim +, actin +
M, 72 [35] Dysphonia for 2 months True vocal cord * FD 6 months vim +, sm-actin +, CD68 
focally +, NR: CK, S100, 
desmin, CD34, LMP
5 M, 3 F with age median of 59 (19–69) [8] Hoarseness, stridor, dysphonia, 
foreign body sensations from 10 
days up to 4 months
* 3+/8 7 cases FD, one case with 
4 relapses in 24 months
All: vim +, sm-actin +, NR: 
CK, S100, desmin, 
myoglobin, CD34
3 further cases, [7] * * * 2 cases FD, one R 12 
months
*
Male (M), Female (F), Cigarette smoking (CS +), Free of disease (FD), Recurrence (R), Vimentin (vim), Cytokeratin (CK), positive (+), no reaction 
(NR), R * not specified or not reported.Diagnostic Pathology 2007, 2:1 http://www.diagnosticpathology.org/content/2/1/1
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2. compact spindle cells in a solid confluent area or as
irregular foci in areas of dense collagen (fibrous histiocy-
toma like)
3. collagen dense pattern similar to desmoid fibromatosis
[7].
Our case of IMT first presented as variant one with relapse
as variant two. Alaani et al. described in a relapsed IMT a
progressive diminution of inflammatory cells, reduction
of atypia and more collagenous, less myxoid stroma up to
osteoblastic changes [10]. A transformation of an IMT to
higher malignancy is possible, especially in cases with
repeated recurrences.
According to Coffin et al., immunohistochemical investi-
gations could reveal an expression of vimentin in 99%,
sm-actin in 92%, focally desmin in 69%, cytokeratins in
36%, CD68 in 24%, and CD30 in 6% [7]. The reported
laryngeal IMT expressed consistently vimentin and actin,
but none of the other markers. Anaplastic lymphoma
kinase (ALK) gene expression is detectable in IMTs, often
in children and young adults under 40 [14-17,21]. Only
two laryngeal IMTs (including our case) have a reported
staining with antibodies against ALK-1. The importance of
ALK expression regarding the prognosis is controversially
discussed. Chun et al. found a better prognosis in cases
with ALK expression [22], whereas Coffin et al. found a
recurrence in 45% of ALK-positive and 20% of ALK-nega-
tive IMTs [16]. The malignant transformation seems inde-
pendent of ALK expression [16].
The differential diagnosis of IMT comprises low grade
myofibroblastic sarcomas as well as a long list of benign,
reactive, or neoplastic spindle cell lesions, such as leiomy-
oma, solitary fibrous tumor, spindle cell carcinoma, nod-
ular fasciitis, and peripheral nerve sheet tumor [20].
Morphology and immunohistochemical profile help to
rule out these entities, whereby low grade myofibroblastic
sarcoma can be difficult to distinguish due to the low or
mild atypia and low proliferations index [23]. The best
discrimination of this malignant neoplasm with favorable
prognosis is the occurrence of local infiltrative growth
[20,23].
As mentioned above, SPC is also an important differential
diagnosis. But if the diagnosis cannot be made on the
basis of conventional histomorphology, it becomes even
more difficult. Typically, SPCs contain pleomorphic
malignant spindle cells with mitoses (including atypical
mitoses). Most of them are associated with epithelial dys-
plasia or common SCC [5]. Our case of SPC showed sim-
ilarities with IMT in some areas. We found only mild
atypia, hypocellular myxoid degeneration and no associa-
tion with dysplasia of the surface epithelium. So we were
not able to diagnose a SPC with HE staining alone. How-
ever, immunohistochemistry was evident for SPC/IMT
(SPC: cytokeratin and vimentin positive, ALK-1 negative
versus IMT: ALK-1 and vimentin positive, cytokeratins
negative). Problems arise in an ambiguous staining pat-
tern: SPCs express cytokeratins only in 40–85% and IMTs
in up to 75% [5,7,8,24-26]. In our SPC, not all pan-cytok-
eratins (MNF 116) were expressed. In such cases, the p63
antibody is helpful [27]. An expression of sm-actin is
reported in SPC and IMT [1,7,8], we found it only in SPC.
In contrast to that, all laryngeal IMTs in literature
expressed actin (table 2). An expression of ALK-1 is typi-
cal, but only one half of IMT are positive. And interest-
ingly, positivity in patients over 40 years is less likely
(whereas IMTs of the head and neck occurs in the 5th/6th
decade) [28,29]. Therefore, even comprehensive immu-
nohistochemical analysis could fail in revealing the right
diagnosis.
Hussong et al. described an overexpression of p53 in one
of six IMT with recurrence and in one of two with malig-
nant transformation, but in none without [30]. Even if
Ledet et al. found p53 only in malignancies but not in
IMTs [31]. But an expression of p53 seems to be not a sure
sign of malignant behavior. Yamamoto et al. described
p53 positivity in 6.7% of all IMTs [29], Brooks et al.
detected it in an oral IMT without recurrence or malig-
nancy [28]. However, the highest number of investigated
IMTs is a study of 24 cases (including six recurrences and
two malignant IMTs) [30]. Therefore, p53 seems to be not
sufficient criterion for differential diagnosis. Bcl-2 expres-
sion is reported in 38% of IMT without relation to recur-
rence or malignant transformation [30]. Expression of
cyclin D1 and Rb was described [18,28], the value of p21
is not assessed. The degree of cellularity, mitoses, and the
extent of inflammatory cells showed no correlation to
more aggressive behavior [30], but the presence of aneu-
ploidy [16], atypia and ganglion-like cells do [30]. Relia-
ble criteria with a high predictive value regarding the
biological behavior of IMTs do not exist so far.
In summary, the differential diagnosis of SPC and IMT can
be difficult, particularly in cases with uncommon immu-
nohistochemical profile. Therefore, a comprehensive
morphological and immunohistochemical analysis is
necessary, but markers of cell cycle (apart from assessment
of proliferation) do not help.
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